Adaptive Biotechnologies (ADPT) Stock Statistics & Valuation Metrics

Adaptive Biotechnologies has a market cap or net worth of $2.03B. The enterprise value is $2.20B.

Adaptive Biotechnologies has 160,044,390 shares outstanding. The number of shares has decreased by -2.65% in one year.

Adaptive Biotechnologies’s return on equity (ROE) is -0.27 and return on invested capital (ROIC) is -13.09%.

The current PE Ratio of Adaptive Biotechnologies is ―. Adaptive Biotechnologies’s PEG ratio is 0.65.

In the last 12 months, Adaptive Biotechnologies had revenue of 276.98M and earned -59.50M in profits. Earnings per share was -0.39.

In the last 12 months, operating cash flow was -27.04M and capital expenditures -2.50M, giving a free cash flow of -29.54M billion.

Adaptive Biotechnologies pays an annual dividend of ―, resulting in a dividend yield of ―

Adaptive Biotechnologies upcoming earnings date is Aug 5, 2026, After Close (Confirmed).

Adaptive Biotechnologies as a current ratio of 3.34, with Debt / Equity ratio of 96.23%

In the past 12 months, Adaptive Biotechnologies has paid 0.00 in taxes.

Adaptive Biotechnologies EV to EBITDA ratio is -89.60, with an EV/FCF ratio of -54.63.

Adaptive Biotechnologies has $218.33M in cash and marketable securities with $208.18M in debt, giving a net cash position of $10.15M billion.

Gross margin is 75.26%, with operating margin of -20.62%, and net profit margin of -21.48%.

The average price target for Adaptive Biotechnologies is $20.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy